Code Pharma's Gammora® Shows Promising Results in HIV Cure
DE BILT, Netherlands & GLASGOW, Scotland — Code Pharma revealed positive outcomes from an eight-week study of its HIV drug, Gammora®, indicating potential for a cellular-level cure. These groundbreaking results were unveiled at the HIV Drug Therapy 2024 Conference in Glasgow.

Breakthrough in HIV Research: Gammora®'s Positive Findings
Code Pharma announced encouraging results from an eight-week trial of Gammora®, its HIV-treatment drug. Presented at the HIV Drug Therapy 2024 Conference, these findings highlight a potential cure for HIV at the cellular level.

Gammora® by Code Pharma: Paving the Way Toward an HIV Cure
Positive eight-week results for Gammora®, Code Pharma’s innovative HIV drug, suggest it may cure the virus at the cellular level. Preliminary data was shared during the HIV Drug Therapy 2024 Conference in Glasgow.

Hope for HIV Cure: Code Pharma Shares Promising Gammora® Data
In a groundbreaking announcement, Code Pharma reported positive results from an eight-week study of its HIV drug, Gammora®, showcasing potential for a cellular-level cure. Findings were presented at the 2024 HIV Drug Therapy Conference.

Code Pharma’s Gammora®: A Step Closer to HIV Eradication
At the HIV Drug Therapy 2024 Conference, Code Pharma unveiled promising eight-week trial results for Gammora®, its HIV drug. The findings suggest a significant advancement toward a cellular-level cure for HIV.

This September, we were featured in the Jerusalem Post, Israel’s most read English newspaper. The publication reviews our clinical trials, the promising results, and the impact Codivir may have on the global pandemic. Read the full article here:

Read the latest feature of Code Pharma in Gulf Today and find out how Codivir was discovered, our successful Phase I results, and where we stand with the Phase II study and emergency approvals from several countries

We were featured in the Global Trend Monitor, a UAE-based business & lifestyle magazine! 
Read the interview with our founder & CEO Zyon Ayni and find out how Zyon founded Code Pharma to develop ground-breaking medical solutions as well as the promising results of our clinical trials regarding Codivir, its safety and effectiveness.

Antiviral drug Codivir shows promising effect against COVID-19

We're going for an IPO and are launching a limited fundraising round for professional investors! Please find all the necessary information in our latest press release